BAGNEUX, France–(Business enterprise WIRE)–Regulatory Information:
GENOMIC Vision (Paris:GV) (FR0011799907 – GV – the “Company”), a biotechnology business that develops equipment and products and services committed to the examination and control of alterations in the genome, nowadays introduced alterations in its governance subsequent the Company’s ordinary standard meeting held on July 11, 2022 at Genomic Vision’s headquarters.
The resolutions put ahead and approved in the course of this common assembly integrated:
- the revocation of Mrs. Remy-Renou’s mandate as Chair of the Govt Board and the appointment of a new member of the Executive Board, Mrs. Emilie Chataignier
- the revocation of the mandates of all the users of the Supervisory Board – Mrs. Elisabeth Ourliac, Mrs. Tammou Abikhzer and Mr. Stéphane Verdood – and the appointment of Mrs. Florence Alouch, Mr. Mohammed Afshar and Mr. Eric Edery for a 6-year phrase as delivered for in the Company’s posts of association.
The reconstituted Supervisory Board fulfilled pursuing the normal standard conference and determined to appoint Mrs. Florence Alouch as Chair of the Supervisory Board and Mr. Aaron Bensimon as Chair of the Govt Board.
The objective of these changes in Genomic Vision’s governance is to improve the Company’s commercial momentum.
The minutes of the everyday general assembly of July 11, 2022 will be created out there in the Buyers / Common Assembly section of the Company’s web site within the statutory timeframe.
ABOUT GENOMIC Vision
GENOMIC Vision is a biotechnology company establishing solutions and providers committed to the examination (structural and purposeful) of genome modifications as very well as to the high quality and basic safety control of these modifications, in specific in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary equipment, dependent on DNA combing know-how and artificial intelligence, supply sturdy quantitative measurements desired to higher assurance characterization of DNA alteration in the genome. These instruments are mostly employed for monitoring DNA replication in cancerous cell, for early most cancers detection and the prognosis of genetic ailments. Genomic Vision, based mostly around Paris in Bagneux, is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For even further details, please visit www.genomicvision.com
Member of the CAC® Mid & Little and CAC® All-Tradable indexes
Ahead Wanting Assertion
This push release consists of implicitly or explicitly specific forward-seeking statements relating to Genomic Vision and its small business. These types of ahead-searching statements are based on assumptions that Genomic Eyesight considers to be fair. However, there can be no assurance that these ahead-wanting statements will be verified, which statements are issue to numerous threats, like the challenges established forth in the “Risk Factors” section of the common registration doc filed with the AMF on April 14, 2022 under reference quantity R.22-0293, as up to date by the amendment submitted with the AMF on May well 20, 2022, underneath amount D.22-0293-A01, offered on the internet internet site of Genomic Vision (www.genomicvision.com) and to the advancement of financial problems, money marketplaces and the marketplaces in which Genomic Vision operates. The forward-seeking statements contained in this press release are also issue to dangers not yet regarded to Genomic Vision or not now thought of materials by Genomic Eyesight. The occurrence of all or portion of this kind of hazards could result in actual outcomes, fiscal problems, general performance or achievements of Genomic Vision to be materially distinctive from these kinds of ahead-wanting statements.
This press launch and the information and facts contained herein do not represent and must not be construed as an supply or an invitation to sell or subscribe, or the solicitation of any buy or invitation to buy or subscribe for Genomic Vision shares in any state. The distribution of this press release in selected international locations may well be a breach of applicable rules. The individuals in possession of this push release will have to inquire about any area constraints and comply with these restrictions.